Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune Resistance
Cancer Medicine · 2025-11 · 14 (21)
DOI: 10.1002/cam4.71317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 29.10.2025. Verfasst von Yi Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Bethune Charitable Foundation, Technical Standards Project of the Science and Technology Commission of Shanghai Municipality, Hospital-level Key Project of Shanghai Pulmonary Hospital.
Abstract (Originalsprache)
Background
Lung cancer remains the leading cause of cancer‐related mortality worldwide. Although immunotherapy has revolutionized lung cancer treatment, its efficacy is often hindered by primary and acquired immune resistance. Increasing evidence indicates that metabolic reprogramming plays a crucial role in tumor progression and the establishment of an immunosuppressive tumor microenvironment in both non‐small cell lung cancer and small cell lung cancer.
Methods
This review comprehensively summarizes recent preclinical and clinical findings on the metabolic alterations associated with immune suppression in lung cancer. The major metabolic pathways—glycolysis, lipid metabolism, and amino acid metabolism—were systematically analyzed, focusing on their regulatory enzymes, signaling pathways, and interactions with immune responses.
Results
Metabolic reprogramming profoundly influences tumor–immune interactions. Enhanced glycolysis, dysregulated lipid synthesis and oxidation, and altered amino acid metabolism collectively contribute to immune evasion by impairing T‐cell activation, promoting regulatory immune cell populations, and modulating cytokine and checkpoint molecule expression.
Conclusion
Targeting tumor metabolic remodeling offers a promising strategy to overcome immune resistance and improve the therapeutic efficacy of immunotherapy in lung cancer. Continued efforts to elucidate the molecular mechanisms linking metabolism and immunity may pave the way for novel combination therapies with durable clinical benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
- Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Förderung
- Beijing Bethune Charitable Foundation
- Technical Standards Project of the Science and Technology Commission of Shanghai Municipality
- Hospital-level Key Project of Shanghai Pulmonary Hospital
- Shanghai Anticancer Association EYAS PROJECT
- Science and Technology Innovation Action Plan of the Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Bai, M., Liu, M., Zhang, Z., Jiang, C., Li, K., Chen, Y., Xu, Y., & Wu, L. (2025). Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune Resistance. Cancer Medicine, 14(21). https://doi.org/10.1002/cam4.71317
Vancouver
Chen Y, Bai M, Liu M, Zhang Z, Jiang C, Li K, et al. Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune Resistance. Cancer Medicine. 2025;14(21). doi:10.1002/cam4.71317
BibTeX
@article{Chen2025,
author = {Chen, Yi and Bai, Menglin and Liu, Ming and Zhang, Zhenshan and Jiang, Chenxue and Li, Kejin and Chen, Yun and Xu, Yaping and Wu, Leilei},
title = {Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune Resistance},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {21},
doi = {10.1002/cam4.71317}
}
EUVIMED